Skip to main content
OpenTrials
Completed

NCT Number: NCT05403489

Comparison of the Results of Bronchoalveolar Lavage Culture and Endotracheal Aspirate Culture in Intubated Critically Ill COVID-19 Patients

Introduction: Secondary pneumonia is frequently seen in COVID-19 cases followed up intubated, and high mortality rates can be observed. Isolation of the agent with bronchoalveolar lavage (BAL) culture or endotracheal aspirate (ETA) culture may increase the success of treatment. This study aimed to retrospectively analyze the results of BAL and ETA cultures in intubated COVID-19 cases.

Methods: We routinely apply BAL culture with bronchoscopy or ETA culture within the first 48 hours after intubating. We retrospectively screened cases who underwent BAL and ETA. They were divided into two groups: Group B and E. Evaluated parameters were compared in both groups.

Results: Demographic data and blood test results were similar in both groups. Intensive care unit (ICU) and intubation durations, and culture positivity were statistically significantly higher in Group B. Although not statistically significant, the mortality rate was higher in Group E. The most growth microorganisms were Candida species.

Conclusion: Mortality rates were consistent with the literature. Since the microorganism isolation rate is higher with BAL and antimicrobial treatment is applied more effectively; early deaths were prevented and stay periods were prolonged. In contrast, these durations were shorter in the ETA group due to higher mortality. In intubated COVID-19 cases, a more effective treatment process can be carried out by clearing the airway with fiberoptic bronchoscopy and by specifically planning the treatment according to the BAL culture. This may have a positive effect on prognosis and mortality.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hisar Intercontinental Hospital

Istanbul, 34768, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Intubated COVID-19 patients
  • Above 18 years old patients

Exclusion criteria

  • Non COVID-19 patients
  • Non intubated COVID-19 patients
  • Below 18 years old patients

Treatment and study plan

Bronchoalveolar lavage

Procedure

In cases approved for bronchoscopy, bronchoalveolar lavage was performed and culture analysis was performed.

Other names: Bronchoalveolar lavage culture, fiberoptic bronchoscopy

endotracheal aspirate culture

Procedure

In cases where consent for bronchoscopy could not be obtained, tracheal secretions were aspirated and culture analysis was performed.

Primary outcomes

  1. Culture positivity

    Time frame: 1 years

    Significantly higher microbiological culture growth rate was obtained in Group B

  2. Length of stay in intensive care unit

    Time frame: 1 years

    Significantly higher duration of stay in intensive care unit was found in Group B

  3. Duration of intubation

    Time frame: 1 years

    Significantly higher duration of stay intubated was observed in Group B

  4. Mortality

    Time frame: 1 years

    Mortality rate was higher in Group E. But not statistically significant.

Secondary outcomes

  1. Microorganism

    Time frame: 1 years

    The most growing microorganism in both groups was the Candida species.

Sponsors and collaborators

Lead sponsor

Basri Cakiroglu

Other

Registry information

Important dates

Study start
2021
Primary completion
2021
Study completion
2022
First posted
Jun 3, 2022
Registry last updated
Jun 3, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.